Fusion protein vaccine
AssigneeLunds Universitets
InventorGunnar Lindahl
Life of this patent
Estimating the term…
Abstract
The present invention relates to the fields of microbiology and vaccine technology, and concerns the development of a vaccine capable of conferring immunity to group B Streptococcus infections. More particularly, the present invention relates to a novel fusion protein, comprising N-terminal region fragments of group B Streptococcus surface proteins, which confers immunity to invasive strains of the group B Streptococcus. It further pertains to an isolated nucleotide sequence encoding said fusion protein; a vector; a host cell; a vaccine; and a method for preventing or treating a group B Streptococcus infection.
Claims26
A fusion protein comprising at least one first N-terminal region fragment of a group B Streptococcus surface protein or analogue, homologue, derivative or immunological related amino acid sequence or fragments thereof, which is fused to at least one second N-terminal region fragment of a group B Streptococcus surface protein or analogue, homologue, derivative or immunological related amino acid sequence or fragments thereof, wherein said first and second at least one N-terminal region fragments of group B Streptococcus surface proteins derive from different group B Streptococcus strains, and wherein said fusion protein is capable of eliciting protective immunity against group B Streptococcus.
A nucleotide sequence comprising:
- at least one first nucleotide sequence as shown in SEQ ID NO:
- 1 or fragments thereof fused to
- at least one second nucleotide sequence as shown in SEQ ID NO:3 or fragments thereof or
- at least one nucleotide sequence as shown in SEQ ID NO:5.
Dependencies are inferred from the claim text.